(MedPage Today) — BERLIN — Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) in patients with BCG-naive, high-risk non-muscle-invasive bladder…
(MedPage Today) — BERLIN — Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) in patients with BCG-naive, high-risk non-muscle-invasive bladder…
Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.
